索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]朱昱润,张春林.骨肉瘤生物标志物研究进展[J].国际骨科学杂志,2021,02:106-109.
点击复制

骨肉瘤生物标志物研究进展(PDF)

《国际骨科学杂志》[ISSN:1673-7083/CN:31-1952/R]

期数:
2021年02期
页码:
106-109
栏目:
综述
出版日期:
2021-04-20

文章信息/Info

Title:
-
作者:
朱昱润; 张春林
211166, 南京医科大学(朱昱润、张春林); 200072, 上海市第十人民医院骨科(朱昱润、张春林)
Author(s):
-
关键词:
骨肉瘤;  生物标志物;  预后;  基因;  蛋白质组学
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-7083.2021.02.010
文献标识码:
-
摘要:
骨肉瘤是青少年人群中常见的高度恶性肿瘤。目前有效诊断骨肉瘤并预测其肺转移和化疗耐药等预后的生物标志物尚不明确,这一现状限制了骨肉瘤患者生存率的进一步提高。骨肉瘤生物标志物类型多样,作用机制各不相同。它们不仅有助于诊断骨肉瘤并预测其预后,而且有助于确定新的骨肉瘤治疗靶点,具有很好的临床应用潜力。该文就近年骨肉瘤生物标记物相关研究进展进行综述,同时阐述这些研究面临的一些问题与挑战。
Abstract:
-

参考文献/References

[1] Li J, Yang Z, Li Y, et al. Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment[J]. Oncotarget, 2016, 7(28): 44763-44778.
[2] Yuan J, Chen L, Chen X, et al. Identification of serum MicroRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma[J]. J Int Med Res, 2012, 40(6): 2090-2097.
[3] Liu W, Zhao X, Zhang YJ, et al. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma[J]. J Int Med Res, 2018, 46(3): 975-983.
[4] Shi ZC, Chu XR, Wu YG, et al. MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA[J]. Tumour Biol, 2015, 36(11): 8579-8584.
[5] Wang Z, Cai H, Lin L, et al. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma[J]. Pediatr Blood Cancer, 2014, 61(2): 206-210.
[6] Shi L, Xie C, Zhu J, et al. Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients[J]. Ann Diagn Pathol, 2020, 46: 151488.
[7] Zhou X, Natino D, Qin Z, et al. Identification and functional characterization of circRNA-0008717 as an oncogene in osteosarcoma through sponging miR-203[J]. Oncotarget, 2018, 9(32): 22288-22300.
[8] Jin J, Chen A, Qiu W, et al. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136[J]. J Cell Biochem,2019, 120(9): 15678-15687.
[9] Zhu KP, Zhang CL, Hu JP, et al. A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma[J]. Int J Biol Sci, 2018, 14(11): 1513-1520.
[10] Li Z, Tang Y, Xing W, et al. LncRNA, CRNDE promotes osteosarcoma cell proliferation, invasion and migration by regulating Notch1 signaling and epithelial-mesenchymal transition[J]. Exp Mol Pathol, 2018, 104(1): 19-25.
[11] Zhao H, Hou W, Tao J, et al. Upregulation of lncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway[J]. Am J Transl Res, 2016, 8(8): 3503-3512.
[12] Yan L, Wu X, Liu Y, et al. LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR-765[J]. J Cell Biochem, 2019, 120(5): 7248-7256.
[13] Tian ZZ, Guo XJ, Zhao YM, et al. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma[J]. Int J Clin Exp Pathol, 2014, 8(11): 15138-15142.
[14] 张鸿程, 宋广元, 谈伟健, 等. IncRNA HOXA11-AS 对骨肉瘤细胞增殖, 迁移和侵袭能力的影响[J]. 中国肿瘤生物治疗杂志, 2017, 24(5): 497-502.
[15] Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis[J]. Biochem Biophys Res Commun, 2018, 495(1): 947-953.
[16] Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2[J]. Cancer Lett, 2017, 396: 66-75.
[17] Fu HL, Shao L, Wang Q, et al. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma[J]. Tumour Biol, 2013, 34(6): 3817-3821.
[18] Ye S, Shen J, Choy E, et al. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines[J]. Cancer Chemother Pharmacol, 2016, 77(2): 349-356.
[19] Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease[J]. Genes Dev, 2008, 22(12): 1662-1676.
[20] Scott MC, Sarver AL, Tomiyasu H, et al. Aberrant retinoblastoma(RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma[J]. J Biol Chem, 2015, 290(47): 28070-28083.
[21] Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma[J]. J Clin Oncol, 1996, 14(2): 467-472.
[22] Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome[J]. J Natl Cancer Inst, 2003, 95(9): 669-674.
[23] Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance[J]. Lancet Oncol, 2012, 13(4): e178-e185.
[24] Martin JW, Chilton-Macneill S, Koti M, et al. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma[J]. PLoS One, 2014, 9(5): e95843.
[25] Zhang J, Yu XH, Yan YG, et al. PI3K/Akt signaling in osteosarcoma[J]. Clin Chim Acta, 2015, 444: 182-192.
[26] Denduluri SK, Idowu O, Wang Z, et al. Insulin-like growth factor(IGF)signaling in tumorigenesis and the development of cancer drug resistance[J]. Genes Dis, 2015, 2(1): 13-25.
[27] Wang YH, Han XD, Qiu Y, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma[J]. J Surg Oncol, 2012, 105(3): 235-243.
[28] Li H, Qiu Z, Li F, et al. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis[J]. Oncol Lett, 2017, 14(5): 5865-5870.
[29] Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets[J]. Tumour Biol, 2013, 34(4): 2041-2051.
[30] Yang JS, Lin CW, Hsieh YS, et al. Selaginella tamariscina(Beauv.)possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways[J]. Food Chem Toxicol, 2013, 59: 801-807.
[31] Kunz P, Sähr H, Lehner B, et al. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma[J]. BMC Cancer, 2016, 16: 223.
[32] Li G, Fu D, Liang W, et al. CYC1 silencing sensitizes osteosarcoma cells to TRAIL-induced apoptosis[J]. Cell Physiol Biochem, 2014, 34(6): 2070-2080.
[33] Fan L, Zhu C, Qiu R, et al. MicroRNA-661 enhances TRAIL or STS induced osteosarcoma cell apoptosis by modulating the expression of cytochrome c1[J]. Cell Physiol Biochem, 2017, 41(5): 1935-1946.
[34] Hu F, Shang XF, Wang W, et al. High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma[J]. Int J Exp Pathol, 2016, 97(1): 86-92.
[35] Hu F, Wang W, Zhou HC, et al. High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma[J]. World J Surg Oncol, 2014, 12: 287.
[36] Cheng DD, Zhang HZ, Yuan JQ, et al. Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis[J]. Oncotarget, 2017, 8(16): 26380-26393.
[37] Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?[J]. BMC Med, 2012, 10: 87.
[38] Brooks JD. Translational genomics: the challenge of developing cancer biomarkers[J]. Genome Res, 2012, 22(2): 183-187.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-04-20